CAICaris Life Sciences, Inc.

$29.66-9.0% 1Y

$29.66

$14.5552 weeks$32.95

CAI in its own filings

Nothing in CAI's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

Events found in the filings · across 131 filings · the record starts in 2024

Hard flags: none
Hard flags
Most recent filing: Sep 14, 2026
Most recent filing · Form 8-K
Record starts: Jul 5, 2024
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 4, 2026
SEC comment-letter activity6 occurrences: 2025-06-13

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 5, 2026Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance.Earnings release · press release
May 7, 2026Caris Life Sciences Reports First Quarter 2026 Financial Results.Earnings release · press release
Apr 2, 2026On April 1, 2026 (the “Closing Date”), Caris Life Sciences, Inc., a Texas corporation (the “Company”) entered into a Financing Agreement, dated as of the Closing Date (the “New Credit Agreement”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time …Material agreement entered · Form 8-K
Feb 26, 2026Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook.Earnings release · press release
Nov 5, 2025Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance.Earnings release · press release
Oct 30, 2025The information set forth under.Shareholder rights modified · Form 8-K